Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2011

01-03-2011

How to improve the immunogenicity of chemotherapy and radiotherapy

Authors: Yuting Ma, Rosa Conforti, Laetitia Aymeric, Clara Locher, Oliver Kepp, Guido Kroemer, Laurence Zitvogel

Published in: Cancer and Metastasis Reviews | Issue 1/2011

Login to get access

Abstract

Chemotherapy or radiotherapy could induce various tumor cell death modalities, releasing tumor-derived antigen as well as danger signals that could either be captured for triggering antitumor immune response or ignored. Exploring the interplay among therapeutic drugs, tumor cell death and the immune cells should improve diagnostic, prognostic, predictive, and therapeutic management of tumor. We summarized some of the cell death-derived danger signals and the mechanism for host to sense and response to cell death in the tumor microenvironment. Based on the recent clinical or experimental findings, several strategies have been suggested to improve the immunogenicity of cell death and augment antitumor immunity.
Literature
1.
2.
Soiffer, R., Hodi, F. S., Haluska, F., Jung, K., Gillessen, S., Singer, S., et al. (2003). Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte–macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. Journal of Clinical Oncology, 21(17), 3343–3350. doi:10.​1200/​JCO.​2003.​07.​005.PubMed
3.
Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., et al. (2003). Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte–macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. Journal of Clinical Oncology, 21(4), 624–630.PubMed
4.
Perez, C. A., Fu, A., Onishko, H., Hallahan, D. E., & Geng, L. (2009). Radiation induces an antitumour immune response to mouse melanoma. International Journal of Radiation Biology, 85(12), 1126–1136. doi:10.​3109/​0955300090324209​9.PubMed
5.
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., et al. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. The Journal of Experimental Medicine, 202(12), 1691–1701. doi:10.​1084/​jem.​20050915.PubMed
6.
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J. L., et al. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Natural Medicines, 13(1), 54–61. doi:10.​1038/​nm1523.
7.
Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., D’Escamard, V., Forni, G., et al. (2008). The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Natural Medicines, 14(6), 676–680. doi:10.​1038/​nm1769.
8.
Correale, P., Cusi, M. G., Tsang, K. Y., Del Vecchio, M. T., Marsili, S., Placa, M. L., et al. (2005). Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. Journal of Clinical Oncology, 23(35), 8950–8958. doi:10.​1200/​JCO.​2005.​12.​147.PubMed
9.
10.
Imaeda, A. B., Watanabe, A., Sohail, M. A., Mahmood, S., Mohamadnejad, M., Sutterwala, F. S., et al. (2009). Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. Journal of Clinical Investigation, 119(2), 305–314. doi:10.​1172/​JCI35958.PubMed
11.
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 418(6894), 191–195. doi:10.​1038/​nature00858.PubMed
12.
Yamasaki, S., Ishikawa, E., Sakuma, M., Hara, H., Ogata, K., & Saito, T. (2008). Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nature Immunology, 9(10), 1179–1188. doi:10.​1038/​ni.​1651.PubMed
13.
Foell, D., Wittkowski, H., Vogl, T., & Roth, J. (2007). S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. Journal of Leukocyte Biology, 81(1), 28–37. doi:10.​1189/​jlb.​0306170.PubMed
14.
Barrat, F. J., Meeker, T., Gregorio, J., Chan, J. H., Uematsu, S., Akira, S., et al. (2005). Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. The Journal of Experimental Medicine, 202(8), 1131–1139. doi:10.​1084/​jem.​20050914.PubMed
15.
Osterloh, A., Veit, A., Gessner, A., Fleischer, B., & Breloer, M. (2008). Hsp60-mediated T cell stimulation is independent of TLR4 and IL-12. International Immunology, 20(3), 433–443. doi:10.​1093/​intimm/​dxn003.PubMed
16.
Basu, S., Binder, R. J., Ramalingam, T., & Srivastava, P. K. (2001). CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity, 14(3), 303–313.PubMed
17.
18.
Chen, C. J., Kono, H., Golenbock, D., Reed, G., Akira, S., & Rock, K. L. (2007). Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Natural Medicines, 13(7), 851–856. doi:10.​1038/​nm1603.
19.
Distler, J. H., Huber, L. C., Gay, S., Distler, O., & Pisetsky, D. S. (2006). Microparticles as mediators of cellular cross-talk in inflammatory disease. Autoimmunity, 39(8), 683–690. doi:10.​1080/​0891693060106153​8.PubMed
20.
Peter, C., Waibel, M., Radu, C. G., Yang, L. V., Witte, O. N., Schulze-Osthoff, K., et al. (2008). Migration to apoptotic “find-me” signals is mediated via the phagocyte receptor G2A. The Journal of Biological Chemistry, 283(9), 5296–5305. doi:10.​1074/​jbc.​M706586200.PubMed
21.
Lauber, K., Bohn, E., Krober, S. M., Xiao, Y. J., Blumenthal, S. G., Lindemann, R. K., et al. (2003). Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell, 113(6), 717–730.PubMed
22.
Yang, D., Chen, Q., Yang, H., Tracey, K. J., Bustin, M., & Oppenheim, J. J. (2007). High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. Journal of Leukocyte Biology, 81(1), 59–66. doi:10.​1189/​jlb.​0306180.PubMed
23.
Orlova, V. V., Choi, E. Y., Xie, C., Chavakis, E., Bierhaus, A., Ihanus, E., et al. (2007). A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. The EMBO Journal, 26(4), 1129–1139. doi:10.​1038/​sj.​emboj.​7601552.PubMed
24.
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Natural Medicines, 13(9), 1050–1059. doi:10.​1038/​nm1622.
25.
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., et al. (2009). Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature, 461(7261), 282–286. doi:10.​1038/​nature08296.PubMed
26.
Gude, D. R., Alvarez, S. E., Paugh, S. W., Mitra, P., Yu, J., Griffiths, R., et al. (2008). Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a “come-and-get-me” signal. The FASEB Journal, 22(8), 2629–2638. doi:10.​1096/​fj.​08-107169.PubMed
27.
Mesaeli, N., & Phillipson, C. (2004). Impaired p53 expression, function, and nuclear localization in calreticulin-deficient cells. Molecular Biology of the Cell, 15(4), 1862–1870. doi:10.​1091/​mbc.​E03-04-0251.PubMed
28.
Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., et al. (2005). Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell, 123(2), 321–334. doi:10.​1016/​j.​cell.​2005.​08.​032.PubMed
29.
30.
Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., et al. (2007). Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death and Differentiation, 14(10), 1848–1850. doi:10.​1038/​sj.​cdd.​4402201.PubMed
31.
Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., et al. (2008). The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death and Differentiation, 15(9), 1499–1509. doi:10.​1038/​cdd.​2008.​67.PubMed
32.
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A. C., Chapman, D. C., et al. (2009). Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. The EMBO Journal, 28(5), 578–590. doi:10.​1038/​emboj.​2009.​1.PubMed
33.
Garrido, C., Brunet, M., Didelot, C., Zermati, Y., Schmitt, E., & Kroemer, G. (2006). Heat shock proteins 27 and 70: Anti-apoptotic proteins with tumorigenic properties. Cell Cycle, 5(22), 2592–2601.PubMed
34.
35.
Spisek, R., & Dhodapkar, M. V. (2007). Towards a better way to die with chemotherapy: Role of heat shock protein exposure on dying tumor cells. Cell Cycle, 6(16), 1962–1965.PubMed
36.
Tesniere, A., Panaretakis, T., Kepp, O., Apetoh, L., Ghiringhelli, F., Zitvogel, L., et al. (2008). Molecular characteristics of immunogenic cancer cell death. Cell Death and Differentiation, 15(1), 3–12. doi:10.​1038/​sj.​cdd.​4402269.PubMed
37.
Doody, A. D., Kovalchin, J. T., Mihalyo, M. A., Hagymasi, A. T., Drake, C. G., & Adler, A. J. (2004). Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. Journal of Immunology, 172(10), 6087–6092.
38.
Murshid, A., Gong, J., & Calderwood, S. K. (2010). Heat shock protein 90 mediates efficient antigen cross presentation through the scavenger receptor expressed by endothelial cells-I. Journal of Immunology, 185(5), 2903–2917. doi:10.​4049/​jimmunol.​0903635.
39.
Chan, T., Chen, Z., Hao, S., Xu, S., Yuan, J., Saxena, A., et al. (2007). Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis. Cancer Gene Therapy, 14(4), 409–420. doi:10.​1038/​sj.​cgt.​7701025.PubMed
40.
Elsner, L., Flugge, P. F., Lozano, J., Muppala, V., Eiz-Vesper, B., Demiroglu, S. Y., et al. (2010). The endogenous danger signals HSP70 and MICA cooperate in the activation of cytotoxic effector functions of NK cells. Journal of Cellular and Molecular Medicine, 14(4), 992–1002. doi:10.​1111/​j.​1582-4934.​2009.​00677.​x.PubMed
41.
Fionda, C., Soriani, A., Malgarini, G., Iannitto, M. L., Santoni, A., & Cippitelli, M. (2009). Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. Journal of Immunology, 183(7), 4385–4394. doi:10.​4049/​jimmunol.​0901797.
42.
43.
Wang, X. Y., Sun, X., Chen, X., Facciponte, J., Repasky, E. A., Kane, J., et al. (2010). Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen. Journal of Immunology, 184(11), 6309–6319. doi:10.​4049/​jimmunol.​0903891.
44.
Kobayashi, N., Karisola, P., Pena-Cruz, V., Dorfman, D. M., Jinushi, M., Umetsu, S. E., et al. (2007). TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity, 27(6), 927–940. doi:10.​1016/​j.​immuni.​2007.​11.​011.PubMed
45.
Gonzalez, N., Bensinger, S. J., Hong, C., Beceiro, S., Bradley, M. N., Zelcer, N., et al. (2009). Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity, 31(2), 245–258. doi:10.​1016/​j.​immuni.​2009.​06.​018.
46.
Shao, W. H., Zhen, Y., Eisenberg, R. A., & Cohen, P. L. (2009). The Mer receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses Gas6 as its ligand for uptake of apoptotic cells. Clinical Immunology, 133(1), 138–144. doi:10.​1016/​j.​clim.​2009.​06.​002.PubMed
47.
Scott, R. S., McMahon, E. J., Pop, S. M., Reap, E. A., Caricchio, R., Cohen, P. L., et al. (2001). Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature, 411(6834), 207–211. doi:10.​1038/​35075603.PubMed
48.
Jinushi, M., Sato, M., Kanamoto, A., Itoh, A., Nagai, S., Koyasu, S., et al. (2009). Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. The Journal of Experimental Medicine, 206(6), 1317–1326. doi:10.​1084/​jem.​20082614.PubMed
49.
Asano, K., Miwa, M., Miwa, K., Hanayama, R., Nagase, H., Nagata, S., et al. (2004). Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in mice. The Journal of Experimental Medicine, 200(4), 459–467. doi:10.​1084/​jem.​20040342.PubMed
50.
Park, D., Tosello-Trampont, A. C., Elliott, M. R., Lu, M., Haney, L. B., Ma, Z., et al. (2007). BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature, 450(7168), 430–434. doi:10.​1038/​nature06329.PubMed
51.
Jinushi, M., Nakazaki, Y., Dougan, M., Carrasco, D. R., Mihm, M., & Dranoff, G. (2007). MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. Journal of Clinical Investigation, 117(7), 1902–1913. doi:10.​1172/​JCI30966.PubMed
52.
Linger, R. M., Keating, A. K., Earp, H. S., & Graham, D. K. (2008). TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Advances in Cancer Research, 100, 35–83. doi:10.​1016/​S0065-230X(08)00002-X.PubMed
53.
Sen, P., Wallet, M. A., Yi, Z., Huang, Y., Henderson, M., Mathews, C. E., et al. (2007). Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood, 109(2), 653–660. doi:10.​1182/​blood-2006-04-017368.PubMed
54.
55.
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., et al. (2008). Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science, 322(5904), 1097–1100. doi:10.​1126/​science.​1164206.PubMed
56.
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., et al. (2007). Differential antigen processing by dendritic cell subsets in vivo. Science, 315(5808), 107–111. doi:10.​1126/​science.​1136080.PubMed
57.
Schnorrer, P., Behrens, G. M., Wilson, N. S., Pooley, J. L., Smith, C. M., El-Sukkari, D., et al. (2006). The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proceedings of the National Academy of Sciences of the United States of America, 103(28), 10729–10734. doi:10.​1073/​pnas.​0601956103.PubMed
58.
McDonnell, A. M., Prosser, A. C., van Bruggen, I., Robinson, B. W., & Currie, A. J. (2010). CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. European Journal of Immunology, 40(6), 1617–1627. doi:10.​1002/​eji.​200940153.PubMed
59.
Merad, M., Ginhoux, F., & Collin, M. (2008). Origin, homeostasis and function of Langerhans cells and other Langerin-expressing dendritic cells. Nature Reviews. Immunology, 8(12), 935–947. doi:10.​1038/​nri2455.PubMed
60.
Idoyaga, J., Suda, N., Suda, K., Park, C. G., & Steinman, R. M. (2009). Antibody to Langerin/CD207 localizes large numbers of CD8alpha+ dendritic cells to the marginal zone of mouse spleen. Proceedings of the National Academy of Sciences of the United States of America, 106(5), 1524–1529. doi:10.​1073/​pnas.​0812247106.PubMed
61.
Flacher, V., Douillard, P., Ait-Yahia, S., Stoitzner, P., Clair-Moninot, V., Romani, N., et al. (2008). Expression of Langerin/CD207 reveals dendritic cell heterogeneity between inbred mouse strains. Immunology, 123(3), 339–347. doi:10.​1111/​j.​1365-2567.​2007.​02785.​x.PubMed
62.
Idoyaga, J., Cheong, C., Suda, K., Suda, N., Kim, J. Y., Lee, H., et al. (2008). Cutting edge: Langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. Journal of Immunology, 180(6), 3647–3650.
63.
Lin, M. L., Zhan, Y., Proietto, A. I., Prato, S., Wu, L., Heath, W. R., et al. (2008). Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset. Proceedings of the National Academy of Sciences of the United States of America, 105(8), 3029–3034. doi:10.​1073/​pnas.​0712394105.PubMed
64.
Farrand, K. J., Dickgreber, N., Stoitzner, P., Ronchese, F., Petersen, T. R., & Hermans, I. F. (2009). Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens. Journal of Immunology, 183(12), 7732–7742. doi:10.​4049/​jimmunol.​0902707.
65.
Henri, S., Poulin, L. F., Tamoutounour, S., Ardouin, L., Guilliams, M., de Bovis, B., et al. (2010). CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. The Journal of Experimental Medicine, 207(1), 189–206. doi:10.​1084/​jem.​20091964.PubMed
66.
Backer, R., Schwandt, T., Greuter, M., Oosting, M., Jungerkes, F., Tuting, T., et al. (2010). Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proceedings of the National Academy of Sciences of the United States of America, 107(1), 216–221. doi:10.​1073/​pnas.​0909541107.PubMed
67.
68.
Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., et al. (2007). Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. The Journal of Experimental Medicine, 204(1), 49–55. doi:10.​1084/​jem.​20062056.PubMed
69.
Schietinger, A., Philip, M., Liu, R. B., Schreiber, K., & Schreiber, H. (2010). Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase. Journal of Experimental Medicine, 207, 2469–2477. doi:10.​1084/​jem.​20092450.PubMed
70.
Spiotto, M. T., Rowley, D. A., & Schreiber, H. (2004). Bystander elimination of antigen loss variants in established tumors. Natural Medicines, 10(3), 294–298. doi:10.​1038/​nm999.
71.
Wu, Y., Wu, W., Wong, W. M., Ward, E., Thrasher, A. J., Goldblatt, D., et al. (2009). Human gamma delta T cells: A lymphoid lineage cell capable of professional phagocytosis. Journal of Immunology, 183(9), 5622–5629. doi:10.​4049/​jimmunol.​0901772.
72.
Brandes, M., Willimann, K., Bioley, G., Levy, N., Eberl, M., Luo, M., et al. (2009). Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proceedings of the National Academy of Sciences of the United States of America, 106(7), 2307–2312. doi:10.​1073/​pnas.​0810059106.PubMed
73.
74.
Saccheri, F., Pozzi, C., Avogadri, F., Barozzi, S., Faretta, M., Fusi, P., et al. (2010). Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Science Translational Medicine, 2(44), 4457. doi:10.​1126/​scitranslmed.​3000739.
75.
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer, 6(1), 24–37. doi:10.​1038/​nrc1782.PubMed
76.
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., et al. (2009). NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. Journal of Clinical Investigation, 119(5), 1251–1263. doi:10.​1172/​JCI36022.PubMed
77.
Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M., et al. (2010). DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. Journal of Immunology, 184(2), 902–911. doi:10.​4049/​jimmunol.​0903225.
78.
Carlsten, M., Baumann, B. C., Simonsson, M., Jadersten, M., Forsblom, A. M., Hammarstedt, C., et al. (2010). Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia, 24(9), 1607–1616. doi:10.​1038/​leu.​2010.​149.PubMed
79.
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001). Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature, 413(6852), 165–171. doi:10.​1038/​35093109.PubMed
80.
Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., et al. (2009). ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood, 113(15), 3503–3511. doi:10.​1182/​blood-2008-08-173914.PubMed
81.
Kato, N., Tanaka, J., Sugita, J., Toubai, T., Miura, Y., Ibata, M., et al. (2007). Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia, 21(10), 2103–2108. doi:10.​1038/​sj.​leu.​2404862.PubMed
82.
Schmudde, M., Braun, A., Pende, D., Sonnemann, J., Klier, U., Beck, J. F., et al. (2008). Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Letters, 272(1), 110–121. doi:10.​1016/​j.​canlet.​2008.​06.​027.PubMed
83.
Fine, J. H., Chen, P., Mesci, A., Allan, D. S., Gasser, S., Raulet, D. H., et al. (2010). Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition. Cancer Research, 70(18), 7102–7113. doi:10.​1158/​0008-5472.​CAN-10-1316.PubMed
84.
Rey, J., Veuillen, C., Vey, N., Bouabdallah, R., & Olive, D. (2009). Natural killer and gammadelta T cells in haematological malignancies: Enhancing the immune effectors. Trends in Molecular Medicine, 15(6), 275–284. doi:10.​1016/​j.​molmed.​2009.​04.​005.PubMed
85.
Pages, F., Galon, J., Dieu-Nosjean, M. C., Tartour, E., Sautes-Fridman, C., & Fridman, W. H. (2010). Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene, 29(8), 1093–1102. doi:10.​1038/​onc.​2009.​416.PubMed
86.
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., et al. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Natural Medicines, 15(10), 1170–1178. doi:10.​1038/​nm.​2028.
87.
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Meng, Y., Beckett, M., et al. (2009). Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood, 114(3), 589–595. doi:10.​1182/​blood-2009-02-206870.PubMed
88.
Takeshima, T., Chamoto, K., Wakita, D., Ohkuri, T., Togashi, Y., Shirato, H., et al. (2010). Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: Its potentiation by combination with Th1 cell therapy. Cancer Research, 70(7), 2697–2706. doi:10.​1158/​0008-5472.​CAN-09-2982.PubMed
89.
90.
91.
Zou, W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer, 5(4), 263–274. doi:10.​1038/​nrc1586.PubMed
92.
Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., et al. (2005). Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Research, 65(8), 3044–3048. doi:10.​1158/​0008-5472.​CAN-04-4505.PubMed
93.
Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., et al. (2004). Derangement of immune responses by myeloid suppressor cells. Cancer Immunology, Immunotherapy, 53(2), 64–72. doi:10.​1007/​s00262-003-0443-2.PubMed
94.
Gabrilovich, D. I., & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology, 9(3), 162–174. doi:10.​1038/​nri2506.PubMed
95.
Chalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Remy-Martin, J. P., et al. (2010). Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. Journal of Clinical Investigation, 120(2), 457–471. doi:10.​1172/​JCI40483.PubMed
96.
Ostrand-Rosenberg, S. (2010). Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity. Cancer Immunology Immunotherapy, 59(10), 1593–1600. doi:10.​1007/​s00262-010-0855-8.
97.
Nagaraj, S., Schrum, A. G., Cho, H. I., Celis, E., & Gabrilovich, D. I. (2010). Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. Journal of Immunology, 184(6), 3106–3116. doi:10.​4049/​jimmunol.​0902661.
98.
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., et al. (2009). Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Research, 69(5), 2000–2009. doi:10.​1158/​0008-5472.​CAN-08-2360.PubMed
99.
100.
Tan, M. C., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., et al. (2009). Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. Journal of Immunology, 182(3), 1746–1755.
101.
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H. I., Antonia, S., et al. (2010). Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. Journal of Clinical Investigation, 120(4), 1111–1124. doi:10.​1172/​JCI40269.PubMed
102.
Machiels, J. P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., et al. (2001). Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Research, 61(9), 3689–3697.PubMed
103.
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., et al. (2004). CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. European Journal of Immunology, 34(2), 336–344. doi:10.​1002/​eji.​200324181.PubMed
104.
Roux, S., Apetoh, L., Chalmin, F., Ladoire, S., Mignot, G., Puig, P. E., et al. (2008). CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. Journal of Clinical Investigation, 118(11), 3751–3761. doi:10.​1172/​JCI35890.PubMed
105.
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., et al. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology, Immunotherapy, 56(5), 641–648. doi:10.​1007/​s00262-006-0225-8.PubMed
106.
Markasz, L., Skribek, H., Uhlin, M., Otvos, R., Flaberg, E., Eksborg, S., et al. (2008). Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. Journal of Immunotherapy, 31(3), 283–293. doi:10.​1097/​CJI.​0b013e3181628b76​.PubMed
107.
108.
109.
110.
Serrone, L., & Hersey, P. (1999). The chemoresistance of human malignant melanoma: An update. Melanoma Research, 9(1), 51–58.PubMed
111.
Plati, J., Bucur, O., & Khosravi-Far, R. (2008). Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. Journal of Cellular Biochemistry, 104(4), 1124–1149. doi:10.​1002/​jcb.​21707.PubMed
112.
Trougakos, I. P., Lourda, M., Antonelou, M. H., Kletsas, D., Gorgoulis, V. G., Papassideri, I. S., et al. (2009). Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clinical Cancer Research, 15(1), 48–59. doi:10.​1158/​1078-0432.​CCR-08-1805.PubMed
113.
114.
Keating, A. K., Kim, G. K., Jones, A. E., Donson, A. M., Ware, K., Mulcahy, J. M., et al. (2010). Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Molecular Cancer Therapeutics, 9(5), 1298–1307. doi:10.​1158/​1535-7163.​MCT-09-0707.PubMed
115.
116.
Lin, C. I., Whang, E. E., Abramson, M. A., Donner, D. B., Bertagnolli, M. M., Moore, F. D., Jr., et al. (2009). Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochemical and Biophysical Research Communications, 379(2), 626–631. doi:10.​1016/​j.​bbrc.​2008.​12.​153.PubMed
117.
118.
119.
120.
121.
122.
123.
124.
Chamoto, K., Takeshima, T., Wakita, D., Ohkuri, T., Ashino, S., Omatsu, T., et al. (2009). Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells. Cancer Science, 100(5), 934–939. doi:10.​1111/​j.​1349-7006.​2009.​01114.​x.PubMed
125.
Conforti, R., Ma, Y., Morel, Y., Paturel, C., Terme, M., Viaud, S., et al. (2010). Opposing effects of Toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Research, 70(2), 490–500. doi:10.​1158/​0008-5472.​CAN-09-1890.PubMed
126.
Sharma, M. D., Baban, B., Chandler, P., Hou, D. Y., Singh, N., Yagita, H., et al. (2007). Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. Journal of Clinical Investigation, 117(9), 2570–2582. doi:10.​1172/​JCI31911.PubMed
127.
Ou, X., Cai, S., Liu, P., Zeng, J., He, Y., Wu, X., et al. (2008). Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. Journal of Cancer Research and Clinical Oncology, 134(5), 525–533. doi:10.​1007/​s00432-007-0315-9.PubMed
128.
Herrmann, A., Kortylewski, M., Kujawski, M., Zhang, C., Reckamp, K., Armstrong, B., et al. (2010). Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Research, 70(19), 7455–7464. doi:10.​1158/​0008-5472.​CAN-10-0736.PubMed
129.
Nam, J. S., Terabe, M., Mamura, M., Kang, M. J., Chae, H., Stuelten, C., et al. (2008). An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Research, 68(10), 3835–3843. doi:10.​1158/​0008-5472.​CAN-08-0215.PubMed
130.
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009). IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. The Journal of Experimental Medicine, 206(7), 1457–1464. doi:10.​1084/​jem.​20090207.PubMed
131.
Yoshio-Hoshino, N., Adachi, Y., Aoki, C., Pereboev, A., Curiel, D. T., & Nishimoto, N. (2007). Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Research, 67(3), 871–875. doi:10.​1158/​0008-5472.​CAN-06-3641.PubMed
132.
Shinriki, S., Jono, H., Ota, K., Ueda, M., Kudo, M., Ota, T., et al. (2009). Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clinical Cancer Research, 15(17), 5426–5434. doi:10.​1158/​1078-0432.​CCR-09-0287.PubMed
133.
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., et al. (2010). Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(17), 7875–7880. doi:10.​1073/​pnas.​1003345107.PubMed
134.
Jin, H. T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S. J., Araki, K., et al. (2010). Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14733–14738. doi:10.​1073/​pnas.​1009731107.PubMed
135.
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., et al. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. The Journal of Experimental Medicine, 207(10), 2175–2186. doi:10.​1084/​jem.​20100637.PubMed
136.
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of Experimental Medicine, 207(10), 2187–2194. doi:10.​1084/​jem.​20100643.PubMed
137.
Derre, L., Rivals, J. P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., et al. (2010). BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. Journal of Clinical Investigation, 120(1), 157–167. doi:10.​1172/​JCI40070.PubMed
138.
139.
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009). Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. The Journal of Experimental Medicine, 206(8), 1717–1725. doi:10.​1084/​jem.​20082492.PubMed
140.
Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., et al. (2009). Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proceedings of the National Academy of Sciences of the United States of America, 106(8), 2729–2734. doi:10.​1073/​pnas.​0813175106.PubMed
141.
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America, 107(9), 4275–4280. doi:10.​1073/​pnas.​0915174107.PubMed
142.
Westwood, J. A., Darcy, P. K., Guru, P. M., Sharkey, J., Pegram, H. J., Amos, S. M., et al. (2010). Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. Journal of Translational Medicine, 8, 42. doi:10.​1186/​1479-5876-8-42.PubMed
143.
Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of Clinical Oncology, 26(32), 5233–5239. doi:10.​1200/​JCO.​2008.​16.​5449.PubMed
144.
Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., et al. (2010). Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of Experimental Medicine, 207(3), 637–650. doi:10.​1084/​jem.​20091918.PubMed
145.
Garcia-Hernandez Mde, L., Hamada, H., Reome, J. B., Misra, S. K., Tighe, M. P., & Dutton, R. W. (2010). Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. Journal of Immunology, 184(8), 4215–4227. doi:10.​4049/​jimmunol.​0902995.
146.
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., et al. (2008). Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood, 112(2), 362–373. doi:10.​1182/​blood-2007-11-120998.PubMed
147.
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., et al. (2005). Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105(8), 3051–3057. doi:10.​1182/​blood-2004-07-2974.PubMed
148.
Pegram, H. J., Jackson, J. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2008). Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. Journal of Immunology, 181(5), 3449–3455.
Metadata
Title
How to improve the immunogenicity of chemotherapy and radiotherapy
Authors
Yuting Ma
Rosa Conforti
Laetitia Aymeric
Clara Locher
Oliver Kepp
Guido Kroemer
Laurence Zitvogel
Publication date
01-03-2011
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9283-2

Other articles of this Issue 1/2011

Cancer and Metastasis Reviews 1/2011 Go to the issue

Acknowledgments

Biography — Wolf H. Fridman, M.D., Ph.D.

OriginalPaper

Tumor microenvironment is multifaceted

OriginalPaper

Modulation of tumor immunity by therapeutic monoclonal antibodies

OriginalPaper

Myeloid cell diversification and complexity: an old concept with new turns in oncology

OriginalPaper

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

OriginalPaper

Immunomodulating antibodies and drugs for the treatment of hematological malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits